HealthTech CFO with extensive public company experience building organizations for growth and value creation Demonstrated success in raising capital, driving profitability, and scaling operations to $500M revenue while ensuring compliance and strengthening financial integrity BROOMFIELD, Colo., Sept. 03, 2025 (GLOBE NEWSWIRE) -- Aclarion, Inc. , (“Aclarion” or the “Company”) (Nasdaq: ACON, ACONW), a healthcare technology... Read More

Nociscan YOY scan volume increased 132% from Q2 2024 to Q2 2025 fueled by new physician adoption and insurance company coverage in the UK Company has achieved two consecutive quarters of scan volume growth for the first time and expects continued QOQ growth for the remainder of the year Cost-effectiveness analysis demonstrating Nociscan is more effective and less costly than provocative discography published in peer-reviewed... Read More

Meeting adjourned to Monday, July 21, 2025 at 9:30 a.m. Mountain Time BROOMFIELD, Colo., July 07, 2025 (GLOBE NEWSWIRE) -- Aclarion, Inc. (“Aclarion” or the “Company”) (Nasdaq: ACON, ACONW), a healthcare technology company that leverages Magnetic Resonance Spectroscopy ("MRS"), artificial intelligence and a proprietary biomarker to optimize clinical treatments for low back and neck pain, today announced that its Annual... Read More

The first CLARITY patient was enrolled at the Texas Back Institute, a world leader in advancing spine technology, science, and education, as well as patient care CLARITY is a randomized clinical trial designed to demonstrate Nociscan’s ability to improve surgical outcomes for chronic low back pain Nociscan aims to become the gold standard in identifying sources of low back pain through MR Spectroscopy (MRS) and Augmented... Read More

Dr. Kris Radcliff to Highlight MR Spectroscopy and Augmented Intelligence (AI)-Based Platform at State of Spine Surgery Think Tank BROOMFIELD, Colo., June 24, 2025 (GLOBE NEWSWIRE) -- Aclarion, Inc. , (“Aclarion” or the “Company”) (Nasdaq: ACON, ACONW), a healthcare technology company that is leveraging biomarkers and proprietary augmented intelligence (AI) algorithms to help physicians identify the location of chronic low... Read More

UHealth — University of Miami Health System and the University of Miami Miller School of Medicine provide world-class research and renowned clinical expertise in spine surgery CLARITY is a prospective, randomized clinical trial designed to demonstrate Nociscan’s ability to improve surgical outcomes for chronic low back pain Nociscan aims to become the gold standard in identifying sources of low back pain through MR... Read More

USC Spine Center, part of Keck Medicine of USC, specializes in treating complex spine conditions with the latest cutting-edge technologies CLARITY is a randomized clinical trial designed to demonstrate Nociscan’s ability to improve surgical outcomes for chronic low back pain Nociscan aims to become the gold standard in identifying sources of low back pain through MR Spectroscopy (MRS) and Augmented Intelligence (AI)... Read More

Texas Back Institute is a world leader in advancing spine technology, science, and education, as well as patient care CLARITY is a randomized clinical trial designed to demonstrate Nociscan’s ability to improve surgical outcomes for chronic low back pain Nociscan aims to become the gold standard in identifying sources of low back pain through MR Spectroscopy (MRS) and Augmented Intelligence (AI) BROOMFIELD, Colo., May 12,... Read More

Advocate Health actively participates in research studies and is an innovator in technology, including spine The CLARITY trial is designed to demonstrate Nociscan’s ability to improve surgical outcomes for chronic low back pain Nociscan aims to become the gold standard in identifying sources of low back pain through MR Spectroscopy (MRS) and Augmented Intelligence (AI) BROOMFIELD, Colo., May 05, 2025 (GLOBE NEWSWIRE) --... Read More

Expands access to first customer using Philips MR Spectroscopy (MRS), demonstrating ease of Nociscan integration across multiple MRS platforms Nociscan now commercially available at 17 sites covering eight states and four countries BROOMFIELD, Colo., April 29, 2025 (GLOBE NEWSWIRE) -- Aclarion, Inc. , (“Aclarion” or the “Company”) (Nasdaq: ACON, ACONW), a healthcare technology company that is leveraging biomarkers and... Read More

BROOMFIELD, Colo., April 23, 2025 (GLOBE NEWSWIRE) -- Aclarion, Inc. , (“Aclarion” or the “Company”) (Nasdaq: ACON, ACONW), a healthcare technology company that is leveraging biomarkers and proprietary augmented intelligence (AI) algorithms to help physicians identify the location of chronic low back pain, will be presenting at the Planet MicroCap Showcase: VEGAS 2025 in partnership with MicroCapClub on Wednesday, April 23,... Read More

Independent Cost-Effectiveness Analysis Concludes Nociscan is Effective and Less Costly Compared to Provocative Discography Conclusions Illustrate Nociscan Saves $1,712 per Patient and Improves Surgical Success by 10% BROOMFIELD, Colo., April 21, 2025 (GLOBE NEWSWIRE) -- Aclarion, Inc. , (“Aclarion” or the “Company”) (Nasdaq: ACON, ACONW), a healthcare technology company that is leveraging biomarkers and proprietary... Read More

BROOMFIELD, Colo., April 09, 2025 (GLOBE NEWSWIRE) -- Aclarion, Inc. , (“Aclarion” or the “Company”) (Nasdaq: ACON, ACONW), a healthcare technology company that is leveraging biomarkers and proprietary augmented intelligence (AI) algorithms to help physicians identify the location of chronic low back pain, today announced that it will be presenting at the Planet MicroCap Showcase: VEGAS 2025 in partnership with MicroCapClub... Read More

MICSC are leaders in Los Angeles providing MRI and Diagnostic Imaging services MICSC expands access to Nociscan beyond Beverly Hills now available in Santa Monica BROOMFIELD, Colo., April 02, 2025 (GLOBE NEWSWIRE) -- Aclarion, Inc. , (“Aclarion” or the “Company”) (Nasdaq: ACON, ACONW) , a healthcare technology company that is leveraging biomarkers and proprietary augmented intelligence (AI) algorithms to help physicians... Read More

Over $20M raised in Q1 with nearly $15M cash on hand No debt, no preferred equity, and no warrants with strike prices near the current market Nasdaq compliant: fully meets bid price and shareholder equity requirements Pivotal CLARITY trial fully funded with initial interim results expected in Q2 2026 BROOMFIELD, Colo., March 31, 2025 (GLOBE NEWSWIRE) -- Aclarion, Inc. , (“Aclarion” or the “Company”) (Nasdaq: ACON, ACONW), a... Read More

BROOMFIELD, Colo., March 26, 2025 (GLOBE NEWSWIRE) -- Aclarion, Inc. , (“Aclarion” or the “Company”) (NASDAQ: ACON, ACONW), a healthcare technology company that is leveraging biomarkers and proprietary augmented intelligence algorithms to help physicians identify the location of chronic low back pain, today announced that effective before market open on Friday March 28, 2025, it will complete a 1-for-27 reverse stock split... Read More

BROOMFIELD, Colo., March 13, 2025 (GLOBE NEWSWIRE) -- Aclarion, Inc. , (“Aclarion” or the “Company”) (Nasdaq: ACON, ACONW) , a healthcare technology company that is leveraging biomarkers and proprietary augmented intelligence (AI) algorithms to help physicians identify the location of chronic low back pain, announced today that it has issued an 8k filing that provides an update for stakeholders to review. The filing can be... Read More

BROOMFIELD, Colo., March 06, 2025 (GLOBE NEWSWIRE) -- Aclarion, Inc. , (“Aclarion” or the “Company”) (Nasdaq: ACON, ACONW) , a healthcare technology company that is leveraging biomarkers and proprietary augmented intelligence (AI) algorithms to help physicians identify the location of chronic low back pain, announced today plans to expand Nociscan access across key markets in New York and New Jersey. The expansion plans... Read More

Agreement expands access to Nociscan technology for leading spine physicians and more than 3.2M people in the greater San Diego Metro area Nociscan leverages MR Spectroscopy (MRS) and Augmented Intelligence (AI) to Identify Sources of Chronic Low Back Pain BROOMFIELD, Colo., March 03, 2025 (GLOBE NEWSWIRE) -- Aclarion, Inc. , (“Aclarion” or the “Company”) (Nasdaq: ACON, ACONW) , a healthcare technology company that is... Read More

BROOMFIELD, Colo., Feb. 28, 2025 (GLOBE NEWSWIRE) -- Aclarion, Inc. ("Aclarion" or the "Company") (NASDAQ: ACON) (NASDAQ: ACONW), a healthcare technology company that leverages Magnetic Resonance Spectroscopy ("MRS"), artificial intelligence and a proprietary biomarker to optimize clinical treatments for low back and neck pain, today announced that its Special Meeting of Stockholders (the “Special Meeting”) scheduled for... Read More

Dr. Nicholas Theodore to highlight NOCISCAN capabilities combining MR Spectroscopy and augmented intelligence (AI) NOCISCAN is an innovative decision support tool that helps physicians personalize treatment for chronic low back pain BROOMFIELD, Colo., Feb. 20, 2025 (GLOBE NEWSWIRE) -- Aclarion, Inc. , (“Aclarion” or the “Company”) (Nasdaq: ACON, ACONW), a healthcare technology company that is leveraging biomarkers and... Read More

Recent Notice of Allowance is for Aclarion’s 24th issued US patent Propionic acid (PA) is a biomarker the literature suggests may be indicative of bacterial infection and pain in an intervertebral disc Patent will expand Aclarion’s proprietary rights to use MRS to measure propionic acid as a biomarker for the identification of potential infection and pain throughout the body BROOMFIELD, Colo., Feb. 11, 2025 (GLOBE NEWSWIRE)... Read More

Northwestern Medicine is a global leader in clinical trial research, including spine CLARITY is a randomized study designed to demonstrate Nociscan’s ability to improve surgical outcomes while reducing costs for chronic low back pain Nociscan aims to become the gold standard in identifying sources of low back pain through MR Spectroscopy (MRS) and Augmented Intelligence (AI) BROOMFIELD, Colo., Feb. 06, 2025 (GLOBE NEWSWIRE)... Read More

The Company has secured nearly $20 million in gross proceeds in 2025 ensuring complete funding for its pivotal CLARITY trial CLARITY is a prospective, randomized, multicenter study to validate Nociscan’s ability to improve surgical outcomes Nociscan aims to become the gold standard in identifying sources of low back pain through MR Spectroscopy (MRS) and Augmented Intelligence (AI) BROOMFIELD, Colo., Feb. 04, 2025 (GLOBE... Read More

Dr. Sigurd Berven to Highlight NOCISCAN Capabilities, Combining MR Spectroscopy and Augmented Intelligence (AI) NOCISCAN as New Gold Standard in Identifying a Source of Discogenic Pain BROOMFIELD, Colo., Jan. 31, 2025 (GLOBE NEWSWIRE) -- Aclarion, Inc. (“Aclarion” or the “Company”) (Nasdaq: ACON, ACONW) , a healthcare technology company that is leveraging biomarkers and proprietary augmented intelligence (AI) algorithms to... Read More

Article Focuses on how Leading Physicians are Incorporating Nociscan Into Their Clinical Practices for Chronic Low Back Pain Patients MAGNETOM Flash is a Peer-to-Peer Magazine Published by Siemens to Showcase Advancing Technologies in the MRI Space The RSNA Edition Coincides With the Annual Meeting of the Radiology Society of North America (RSNA) BROOMFIELD, Colo., Nov. 21, 2024 (GLOBE NEWSWIRE) -- Aclarion, Inc. ,... Read More

BROOMFIELD, CO / ACCESSWIRE / November 14, 2024 / Aclarion, Inc., ("Aclarion" or the "Company") (Nasdaq:ACON) (Nasdaq:ACONW), a healthcare technology company that is leveraging biomarkers and proprietary augmented intelligence (AI) algorithms to help physicians identify the location of chronic low back pain, today announced its participation at the upcoming Virtual Investor Summit Microcap Event on November 21 st . The... Read More

Fireside Chat Scheduled for 2:00 PM ET on October 15, 2024 BROOMFIELD, Colo., Oct. 10, 2024 (GLOBE NEWSWIRE) -- Aclarion, Inc. , (“Aclarion” or the “Company”) (Nasdaq: ACON, ACONW), a healthcare technology company that is leveraging biomarkers and proprietary augmented intelligence (AI) algorithms to help physicians identify the location of chronic low back pain, announced today that Aclarion’s CEO, Brent Ness, has been... Read More

Modic Changes (MC) are MRI Findings Associated With Endplate Damage, Neoinnervation, and Chronic Low Back Pain (cLBP) MR Spectroscopy (MRS) Measurement of Intradiscal Propionic Acid (PA) can Clarify MC Etiology and Help Stratify MC Patients to Potentially Inform Better Treatment Decisions for cLBP Patients Results Presented at the 50th International Society for the Study of the Lumbar Spine (ISSLS) Annual Meeting 2024... Read More

Successful milestones achieved and upcoming include peer-reviewed publications, commercial agreements, and payer coverage decisions Progressing with proven path toward standard of care addressing chronic low back pain, the largest expenditure in US healthcare costing Americans an estimated $134 Billion annually More than $50 Million has been invested in the promising Aclarion AI platform that aids physicians in... Read More

Initial LIFEHAB Enrolled Patients Receive Nociscan Exams to Help Evaluate How Biomarkers in the Discs of the Lumbar Spine Correspond With Treatment Response LIFEHAB is a Randomized Controlled Trial in Norway Comparing Lumbar Interbody Fusion Surgery With Multidisciplinary Rehabilitation LIFEHAB Joins the NIH and Rome in Selecting Nociscan as a Technology to Help Determine Which Discs to Treat and the Technology’s Role in... Read More

Justin Kubeck, M.D. of Ocean Pain and Spine in Toms River, NJ Will Lead a Statewide Network of Providers That Use Nociscan to Better Serve This Important Segment of Low Back Pain Population Average Settlement in New Jersey for Personal Injury Claims Involving the Neck and Back is $918,967 Work-related Accidents Which Cause Neck and Back Injuries Have a National Average Settlement of $148,750 BROOMFIELD, CO, Sept. 05, 2024... Read More

CLUE is a Multi-center Trial to Identify how Often Nociscan’s AI Data Changes the Initial Treatment Plan for Patients With Chronic Low Back Pain Dr. Justin Kubeck Will Initiate CLUE in New Jersey at Ocean Pain and Spine in Toms River BROOMFIELD, CO, Aug. 29, 2024 (GLOBE NEWSWIRE) -- Aclarion, Inc. , (“Aclarion” or the “Company”) (Nasdaq: ACON, ACONW), a healthcare technology company that is leveraging biomarkers and... Read More

Surgeons Will Determine Their Surgical Treatment Plan Before Nociscan and Report on How Often the Surgical Plan Changes After Receiving Nociscan Data Multiple Physicians and Sites Will Enroll in CLUE in the Coming Months Adding Practical Real-world Data to Aclarion’s Expanding Body of Clinical Evidence BROOMFIELD, CO, Aug. 21, 2024 (GLOBE NEWSWIRE) -- Aclarion, Inc. , (“Aclarion” or the “Company”) (Nasdaq: ACON, ACONW), a... Read More

BROOMFIELD, CO, Aug. 15, 2024 (GLOBE NEWSWIRE) -- Aclarion, Inc. (“Aclarion” or the “Company”) (Nasdaq: ACON, ACONW), a healthcare technology company that is leveraging biomarkers and proprietary augmented intelligence algorithms to help physicians identify the location of chronic low back pain, announced today that it will be presenting at the upcoming Virtual Investor Summit on August 20 th , 2024. Investors may request a... Read More

Sheridan Community Hospital is the First Healthcare Institution in Michigan With Nociscan Agreement Expands Nociscan Access to John Keller, MD, a Leading Neurosurgeon and Aclarion Medical Advisor, and the Patients he Serves in Central Michigan BROOMFIELD, CO, Aug. 14, 2024 (GLOBE NEWSWIRE) -- Aclarion, Inc. , (“Aclarion” or the “Company”) (Nasdaq: ACON, ACONW), a healthcare technology company that is leveraging biomarkers... Read More

Vitality is a top 4 Provider of Private Medical Insurance in the UK. Aclarion now has Payer Coverage From 3 of the 4 Largest Private Health Insurers in the UK. Nearly 60% of all Patients With Private Health Insurance in the Greater London Market now Have Access to Aclarion’s Nociscan. BROOMFIELD, CO, Aug. 13, 2024 (GLOBE NEWSWIRE) -- Aclarion, Inc., (“Aclarion” or the “Company”) (Nasdaq: ACON, ACONW) , a healthcare... Read More

Aviva is a Top 4 Provider of Private Medical Insurance in the UK By Joining AXA, Approximately 45% of Patients With Private Insurance Now Have Access to Nociscan in the Greater London Spine Care Market BROOMFIELD, CO, July 09, 2024 (GLOBE NEWSWIRE) -- Aclarion, Inc. , (“Aclarion” or the “Company”) (Nasdaq: ACON, ACONW), a healthcare technology company that is leveraging biomarkers and proprietary augmented intelligence... Read More

AXA is the 2 nd Largest Provider of Private Medical Insurance in the UK Payer Coverage is the Most Important Catalyst Aclarion can Achieve to Drive Volume and Revenue AXA Represents the First Insurance Company to Approve Payment for Nociscan BROOMFIELD, CO, June 26, 2024 (GLOBE NEWSWIRE) -- Aclarion, Inc. , (“Aclarion” or the “Company”) (Nasdaq: ACON, ACONW), a healthcare technology company that is leveraging biomarkers and... Read More

Established in 1932, the London Clinic is the UK’s Most Renowned Independent, Private Hospital Payment to Aclarion for Each Nociscan is Being Increased From the Original Contract Contract Extension Aligns Aclarion and The London Clinic With Engaging Payers to Increase Access to Nociscan for Both Patients and Referring Physicians BROOMFIELD, CO, June 25, 2024 (GLOBE NEWSWIRE) -- Aclarion, Inc. , (“Aclarion” or the “Company”)... Read More

LIFEHAB is a randomized controlled trial in Norway comparing lumbar interbody fusion surgery with multidisciplinary rehabilitation Norway is a single-payer national health insurance system LIFEHAB is targeting enrollment to begin in the second quarter of 2024 BROOMFIELD, CO, April 25, 2024 (GLOBE NEWSWIRE) -- via NewMediaWire -- Aclarion, Inc. , (“Aclarion” or the “Company”) (Nasdaq: ACON, ACONW), a healthcare technology... Read More

Confirms predictive value of Nociscan for identifying painful discs. Nociscan demonstrated a sensitivity of 100% and a specificity of 80% compared to provocative discography (PD), suggesting Nociscan provides better information to surgeons. BROOMFIELD, CO, March 04, 2024 (GLOBE NEWSWIRE) -- via NewMediaWire -- Aclarion, Inc., (“Aclarion” or the “Company”) (Nasdaq: ACON, ACONW), a healthcare technology company that is... Read More

BROOMFIELD, CO, Feb. 27, 2024 (GLOBE NEWSWIRE) -- via NewMediaWire - Aclarion, Inc. (“Aclarion” or the “Company”) (Nasdaq: ACON, ACONW) , a healthcare technology company that is leveraging biomarkers and proprietary augmented intelligence algorithms to help physicians identify the location of chronic low back pain, today announced the closing of its public offering of 5,175,000 units, with each unit consisting of one share... Read More

BROOMFIELD, CO, Feb. 26, 2024 (GLOBE NEWSWIRE) -- via NewMediaWire -- Aclarion, Inc. (“Aclarion” or the “Company”) (Nasdaq: ACON, ACONW), a healthcare technology company that is leveraging biomarkers and proprietary augmented intelligence algorithms to help physicians identify the location of chronic low back pain, today announced the pricing of its public offering of 5,175,000 units, with each unit consisting of one share... Read More

Company is initiating its pivotal multicenter, prospective, randomized CLARITY trial to build on clinical evidence demonstrating superior surgical outcomes when Nociscan is utilized in surgical decisioning 5 additional Key Opinion Leader (KOL) surgeons expected to adopt Nociscan through the Alphatec strategic partnership in 1H24 BROOMFIELD, CO, Feb. 05, 2024 (GLOBE NEWSWIRE) -- via NewMediaWire -- Aclarion, Inc. ,... Read More

Dr. Uribe is Chief of the Division of Spinal Disorders, Volker K. H. Sonntag Chair of Spine Research, and Vice Chairman of Neurosurgery at Barrow Neurological Institute Dr. Uribe Becomes Aclarion’s 3 rd KOL With Access to a Diagnostic Center Authorized to Perform Nociscans BROOMFIELD, CO, Jan. 22, 2024 (GLOBE NEWSWIRE) -- via NewMediaWire – Aclarion, Inc. (“Aclarion” or the “Company”) (Nasdaq: ACON, ACONW), a healthcare... Read More

Nociscan is the first augmented intelligence platform to measure pain biomarkers in the lumbar spine This new product release expands accessibility of Nociscan on the worldwide MR market Builds on preexisting compatibility with Siemens BROOMFIELD, CO, Jan. 17, 2024 (GLOBE NEWSWIRE) -- via NewMediaWire -- Aclarion, Inc. , (“Aclarion” or the “Company”) (Nasdaq: ACON, ACONW), a healthcare technology company that is leveraging... Read More

Partnership aims to include Aclarion’s surgical decision support technology within ATEC’s AlphaInformatiX platform to better inform spine surgery Aclarion’s Nociscan is the first augmented intelligence platform to measure pain biomarkers in the lumbar spine to help physicians identify the location of chronic low back pain BROOMFIELD, CO, Jan. 08, 2024 (GLOBE NEWSWIRE) -- via NewMediaWire -- Aclarion, Inc. , (“Aclarion” or... Read More

BROOMFIELD, CO, Jan. 02, 2024 (GLOBE NEWSWIRE) -- via NewMediaWire -- Aclarion, Inc. (“Aclarion” or the “Company”) (Nasdaq: ACON, ACONW), a healthcare technology company that is leveraging biomarkers and proprietary augmented intelligence algorithms to help physicians identify the location of chronic low back pain, today announced that effective before market open on Thursday January 4, 2024, it will complete a 1-for-16... Read More

Pace of Nociscan orders accelerated 2.5x for the last 250 scans compared to the first 250 scans Further acceleration of scan volumes expected as MRIs are activated for the recently completed panel of 10 Key Opinion Leader (KOL) surgeons All commercial Nociscans to date have been completed on Siemens MRI scanners with additional acceleration of volumes expected as Philips scanners are onboarded BROOMFIELD, CO, Nov. 27, 2023... Read More

Recruitment of a panel of leading KOL surgeons who believe Nociscan can improve the diagnosis and treatment of discogenic low back pain is a critical step to establishing Nociscan as standard of care. Aclarion’s KOL panel represents spine surgeons at some of the largest and most influential academic centers and private practices in the country, including leaders of national societies that advocate for protocols to improve... Read More

Dr. Hartl is the Hansen-MacDonald Professor of Neurological Surgery and Director of Spinal Surgery at the Weill Cornell Brain and Spine Center in New York, and the co-director of New York-Presbyterian Och Spine. Dr. Hartl becomes Aclarion’s 2 nd KOL to get access to an MRI center authorized to perform Nociscans, adding NYC to Denver as the second active KOL site. Aclarion will report on Nociscan volumes to date before the... Read More

The Helping to End Addiction Long-term® Initiative, or NIH HEAL Initiative®, is funding ground-breaking low back pain research. The Back Pain Consortium (BACPAC) Research Program, a recipient of the NIH HEAL Initiative, is an effort to address the need for effective and personalized therapies for chronic low back pain (cLBP). Two BACPAC trials utilizing Aclarion’s Nociscan platform include the Biomarkers for Evaluating Spine... Read More

Porter Hospital Becomes First Facility in Denver to Give Chronic Low Back Pain Patients Access to Revolutionary Nociscan Technology That Measures Biomarkers to Pinpoint the Source of Pain George Frey, MD Becomes Aclarion’s First KOL Surgeon to Onboard a Hospital MRI to add Nociscan Data to his Treatment Decisioning Process for Chronic Low Back Pain Patients Published Clinical Data Demonstrates That Patient Outcomes are... Read More

Nociscan cost-effectiveness abstract poster highlights dominance over provocative discography. The 45 th Annual Society for Medical Decision Making (SMDM) Meeting is being held October 22-25, 2023. Founded in 1979, SMDM promotes scientific and methodological rigor in health care decision research and its application to health policy and clinical care. Highlighting the importance of the cost savings and improved outcomes... Read More

Partnership aims to include Aclarion’s Nociscan surgical decisioning technology within ATEC’s AlphaInformatiX platform to better inform spine surgery ATEC is a medical device company dedicated to revolutionizing the approach to spine surgery through clinical distinction Aclarion’s Nociscan is the first augmented intelligence platform to measure disc health biomarkers in the lumbar spine to help physicians identify the... Read More

Aclarion is steadily executing on a proven path toward standard of care. Ten prominent Key Opinion Leader (KOL) surgeons have formally engaged to partner with the company to drive market traction and reimbursement. Company is poised to report the critical metrics that drive the key catalysts of value creation. BROOMFIELD, CO, Oct. 02, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire -- Aclarion, Inc. , (“Aclarion” or the “Company”)... Read More

BROOMFIELD, CO, Aug. 25, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire -- Aclarion, Inc. , (“Aclarion” or the “Company”) (Nasdaq: ACON, ACONW), a healthcare technology company that is leveraging biomarkers and proprietary augmented intelligence algorithms to help physicians identify the location of chronic low back pain, announced today that it was not able to file its Quarterly Report for the quarter ended June 30, 2023 by the... Read More

BROOMFIELD, CO, June 14, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire – Aclarion, Inc. (“Aclarion” or the “Company”) (Nasdaq: ACON, ACONW), a healthcare technology company that is leveraging biomarkers and proprietary augmented intelligence algorithms to help physicians identify the location of chronic low back pain, announced today their commercial agreement with The Imaging Center in Grand Rapids, MI. The Imaging Center is a... Read More

Nociscan cost-effectiveness abstract highlights dominance over provocative discography and can save the US healthcare system $283M to $441M annually. The International Society for the Advancement of Spine Surgery (ISASS) Annual Meeting was held June 1-3, 2023. ISASS Policy Statement on Lumbar Spinal Fusion Surgery acknowledges MR Spectroscopy as an effective alternative to provocative discography. BROOMFIELD, CO, June 08,... Read More

The London Clinic is the UK’s most renowned independent, private hospital, established 1932. The London Spine Clinic is first specialist spinal unit established in England, 1997. The London Clinic will be Aclarion’s first customer in London. BROOMFIELD, CO, May 30, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire – Aclarion, Inc. , (“Aclarion” or the “Company”) (Nasdaq: ACON, ACONW), a healthcare technology company that is... Read More

Development of This Program Supports Aclarion’s Commitment to Lead With Strong Clinical Evidence and Engage the Payer Community Through Key Opinion Leader Advocacy Aclarion to Participate in Upcoming ISASS 2023 on June 1-3, 2023 in San Francisco, CA Where Their Health Economics Outcomes Abstract Will be Presented BROOMFIELD, CO, May 23, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire – Aclarion, Inc. , (“Aclarion” or the... Read More

BROOMFIELD, CO, May 23, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire – Aclarion, Inc. , (“Aclarion” or the “Company”) (Nasdaq: ACON, ACONW), a healthcare technology company that is leveraging biomarkers and proprietary augmented intelligence algorithms to help physicians identify the location of chronic low back pain, announced today that it will not file its Quarterly Report for the quarter ended March 31, 2023 within the... Read More

Up to $2M Unsecured, Non-Convertible Bridge Debt With No Required Amortization Payments Financing Supports Execution of the 2023 Plan and the Achievement of Critical Milestones in Support of Definitive Growth Capital BROOMFIELD, CO, May 19, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire – Aclarion, Inc., (“Aclarion” or the “Company”) (Nasdaq: ACON, ACONW), a healthcare technology company that is leveraging biomarkers and... Read More

Nicholas Theodore, MD, FACS, FAANS, is Director of Neurosurgical Spine Center, Johns Hopkins, and Professor of Neurosurgery, Orthopaedics and Biomedical Engineering CLARITY is a Post-market, Multi-site Trial That Will Further Evaluate the Role of Nociscan in the Diagnosis and Surgical Ttreatment of Chronic Low Back Pain. CLARITY is Targeted to Begin in the Second Half of 2023. BROOMFIELD, CO, May 02, 2023 (GLOBE NEWSWIRE) --... Read More

Nociscan™ is the first evidence-supported SaaS platform to objectively measure discogenic biomarkers for insight into pathological low back pain. Nociscan provides decision support to help bridge a major diagnostic void. Sigurd Berven, MD will speak to groundbreaking clinical and economic evidence of Nociscan. Jeff Lotz, PhD will speak to the foundational science behind Aclarion’s proprietary solution. BROOMFIELD, CO, April... Read More

Success rate at 2 years for discogenic low back pain surgeries was 85% for patients whose treatment strategy was consistent with Nociscan-identified discs, a 22 percentage point improvement over patients whose treatment strategy was inconsistent with Nociscan-identified discs (85% vs. 63%; p=0.07) Nociscan is the first augmented intelligence platform to measure pain biomarkers in the lumbar spine BROOMFIELD, CO, April 24,... Read More

Marks the eighth advisor to growing KOL program to build strong body of clinical evidence and support US commercialization Aclarion to participate in upcoming SPINEWEEK 2023 Broomfield, CO, March 07, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire – Aclarion, Inc. , (“Aclarion” or the “Company”) (Nasdaq: ACON, ACONW), a healthcare technology company that is leveraging biomarkers and proprietary augmented intelligence algorithms to... Read More

BROOMFIELD, CO / ACCESSWIRE / February 16, 2023 / Aclarion, Inc., ("Aclarion" or the "Company") (NASDAQ:ACON) (NASDAQ:ACONW), a healthcare technology company that is leveraging biomarkers and proprietary augmented intelligence algorithms to help physicians identify the location of chronic low back pain (CLBP), has been invited to present at the Third Annual Winter Wonderland - Best Ideas Virtual Investor conference, which is... Read More

Nociscan TM is the first evidence-supported SaaS platform to objectively measure discogenic biomarkers for insight into pathological pain. Nociscan provides decision support to help bridge a major diagnostic void. Robert Eastlack, MD will speak to his real-world experience using Nociscan to effectively evaluate CLBP. BROOMFIELD, CO , Feb. 15, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire – Aclarion, Inc. , (“Aclarion” or the... Read More

Director of Endoscopic Spine Surgery at the University of Miami Broomfield, CO, Jan. 31, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire -- Aclarion, Inc. , (“Aclarion” or the “Company”) (Nasdaq: ACON, ACONW), a healthcare technology company that is leveraging biomarkers and proprietary augmented intelligence algorithms to help physicians identify the location of chronic low back pain, announced today that Gregory Basil, MD,... Read More

Broomfield, CO, Jan. 17, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire -- Aclarion, Inc. (“Aclarion” or the “Company”) (Nasdaq: ACON, ACONW), a healthcare technology company that is leveraging biomarkers and proprietary augmented intelligence algorithms to help physicians identify the location of chronic low back pain, announced today that George Frey MD, Founder of the Colorado Comprehensive Spine Institute, will advise the... Read More

Broomfield, CO, Dec. 22, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire -- Aclarion, Inc., (“Aclarion” or the “Company”) (Nasdaq: ACON, ACONW), a healthcare technology company that is leveraging biomarkers and proprietary augmented intelligence algorithms to help physicians identify the location of chronic low back pain, announced today that Dr. Christopher Ames, Director of Spinal Deformity and Spine Tumor Surgery and... Read More

Development of this program supports Aclarion’s commitment to lead with strong clinical evidence and engage the payer community through key opinion leader advocacy. Broomfield, CO, Dec. 21, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire -- Aclarion, Inc. (“Aclarion” or the “Company”) (Nasdaq: ACON, ACONW), a healthcare technology company that is leveraging biomarkers and proprietary augmented intelligence algorithms to help... Read More

Dr. Uribe is the fourth national KOL to join the Aclarion team this year. Development of this program supports Aclarion’s commitment to lead with strong clinical evidence and engage the payer community through key opinion leader advocacy. Broomfield, CO, Dec. 19, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire -- Aclarion, Inc., (“Aclarion” or the “Company”) (Nasdaq: ACON, ACONW), a healthcare technology company that is leveraging... Read More